study of sacituzumab govitecan for triple-negative breast cancer
Published 3 years ago • 2K plays • Length 5:16Download video MP4
Download video MP3
Similar videos
-
3:41
what is triple-negative breast cancer? | dana-farber cancer institute
-
5:42
study of saci-io for triple negative metastatic breast cancer
-
56:00
metastatic breast cancer forum 2018: triple negative breast cancer | dana-farber cancer institute
-
4:59
study of saci-io for hormone receptor positive metastatic breast cancer
-
1:18
esmo22: breast cancer research by sara tolaney, md (tropics) | dana-farber cancer institute
-
1:03:16
triple negative breast cancer | dana-farber cancer institute
-
1:06:13
metastatic breast cancer forum 2017, triple negative breast cancer | dana-farber cancer institute
-
0:46
oncotarget: sacituzumab govitecan in triple-negative breast cancer
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
7:40
study of carboplatin plus nivolumab in metastatic triple-negative breast cancer
-
33:41
clinical trials for metastatic breast cancer: what you should know | dana-farber cancer institute
-
1:49
final os analysis of sacituzumab govitecan in tropics-02
-
2:15
ascent: sacituzumab govitecan biomarker analysis
-
22:26
triple-negative breast cancer: what's new in treatment and research at mbc patient forum 2019
-
2:23
dr aditya bardia discusses the advantages of sacituzumab govitecan for triple-negative breast cancer
-
1:36
real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
-
2:33
saci-io hr : ana garrido-castro, md | dana-farber cancer institute
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
-
1:00
tropics-02: sacituzumab govitecan in hr /her- breast cancer